|
|
|
| home > ebr > Winter 2009 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Independent consultant Emile Bellott looks at the changing biotech
landscape in light of the global financial crisis and considers the
likely implications for the global pharmaceutical/biotech industry |
|
|
| Mark B Hassenplug and Kai Gindner at Ernst & Young examine ways in which
pharmaceutical companies can maintain standards in supply chain management |
|
|
|
| Pharma and biotech companies often manage scientific assets and equipment on their own. Bob Moore at GE
Healthcare discusses why and how outsourcing scientific asset services can help to improve effectiveness in the lab |
|
|
| Catherine D’Arcy at PA Consulting Group describes the requirement for greater
efficiency and effectiveness in R&D operations and how working closely with
a global pharmaceutical company has prompted a review of key functions |
|
|
| Richard Barratt at Barratt Legal examines the proliferation of outsourcing
operational practices in the industry, and tells us how to get the best out of it |
|
|
|
| Mats Hellström and Björn Frendéus at BioInvent International examine the developments that
are occurring in monoclonal antibody drugs, and discuss their future in the fight against cancer |
|
|
| Birgit Jehn at QIAGEN GmbH gives an overview on HLA-Typing
or pre-therapeutic testing in AIDS patients |
|
|
|
|
| David Bunton and Lee Rankin at Biopta Ltd and Alistair Corbett at Glasgow
Caledonian University discuss opioid receptors as drug targets in gastrointestinal disorders |
|
|
| Graham Lappin at Xceleron argues that microdosing can provide important information about
a drug’s behaviour before Phase I, thereby reducing the likelihood of costly failures at a later stage |
|
|
|
| Ulrich Braumann at Bruker BioSpin and Herbert Thiele at Bruker Daltonik analyse
structure verification of small molecules using integrated MS spectrometry and NMR spectroscopy |
|
|
| Josep Prous at Thomson Reuters introduces biomarkers, identifying them
as a crucial factor in the evolution of drug research and development |
|
|
| LABALisette
Oversteegen at Datamonitor discusses combination
product market trends in the respiratory drug sector |
|
|
|
| R Keith Williams at The Clinical Biotechnology Centre, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and Angela Osborne of eXmoor pharma concepts ltd discuss small-scale biomanufacturing for clinical trials, cell and gene therapies in the UK market |
|
|
| Kate Westwell and Gina Wenham at Eden Biodesign explain
how implementing the quality cycle can deliver product value |
|
|
|
| Jacques Lhomel of Biocitech tells how one of Europe’s high-profile
life science parks has boosted resources for life sciences R&D |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Staffordshire company Woolcool wins 2018 Queen’s Award for Innovation
The world is crying out for genuinely sustainable alternatives to manmade plastic packaging, so the winning of a Queen’s Award for Enterprise in Innovation by Staffordshire company Woolcool demonstrates the very real credibility of using a natural, renewable packaging resource – sheeps wool. First conceived by founder and CEO Angela Morris in 2001, Woolcool is a superior insulated packaging solution for the transportation of temperature-sensitive goods for the food and pharmaceutical sectors.
More info >> |
|
 |
White Papers |
 |
|
Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences
CIDP (Centre International de Développement Pharmaceutique)
Mauritius, the tropical island situated in the Indian Ocean and known
worldwide for its beautiful beaches, is also internationally recognised
for its rule of law, and political and social stability. Over the past
few years, the economy has been successfully transitioned from a
monocrop to a diversified innovation-driven and knowledge-based economy,
resting on agribusiness, export-oriented manufacturing, tourism,
financial services, property development and real estate, ICT-BPO, the
seafood industry, a free port, logistics and a nascent ocean economy.
Emerging sectors such as healthcare and life sciences are presenting
some niche areas for the taking, and the enabling environment is being
put in place to make it happen - especially in the light of sustained
growth within pharmaceutical, medical device, and clinical research.
Important
international players are already in operation locally as the country
has established the appropriate legal and regulatory frameworks based on
international norms, for the development of a strong biomedical
research sector.
More info >> |
|
 |
Industry Events |
 |
DIA 2018 Global Annual Meeting
24-28 June 2018, Boston, MA
The DIA 2018 Global
Annual Meeting brings together thousands of innovators from around the globe.
Designed to drive insights into action by connecting key policy discussions to
real-world knowledge that you need to do your job every day, your attendance
will accelerate your growth and your organization's performance in the
development ecosystem.
More info >> |
|
|
